Jacobs Levy Equity Management Inc. Invests $870,000 in Omnicell, Inc. $OMCL

Key Points

• Jacobs Levy Equity Management Inc. invested $870,000 in Omnicell, acquiring 24,884 shares, which represents approximately 0.05% of the company's stock as of their latest SEC filing.
• Wells Fargo & Company raised Omnicell's target price from $37 to $40, citing an "overweight" rating, while multiple other analysts have varying ratings reflecting a mixed market outlook.
• Omnicell reported earnings of $0.45 per share, exceeding estimates, with a year-over-year revenue growth of 5%, indicating positive financial momentum for the company.

Jacobs Levy Equity Management Inc. purchased a new position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 24,884 shares of the company's stock, valued at approximately $870,000. Jacobs Levy Equity Management Inc. owned approximately 0.05% of Omnicell as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Point72 Hong Kong Ltd acquired a new stake in shares of Omnicell in the fourth quarter worth $101,000. AlphaQuest LLC lifted its stake in shares of Omnicell by 79.0% in the first quarter. AlphaQuest LLC now owns 6,400 shares of the company's stock worth $224,000 after buying an additional 2,824 shares during the last quarter. New Age Alpha Advisors LLC acquired a new stake in shares of Omnicell in the first quarter worth $233,000. EntryPoint Capital LLC lifted its stake in shares of Omnicell by 21.6% in the first quarter. EntryPoint Capital LLC now owns 6,671 shares of the company's stock worth $233,000 after buying an additional 1,184 shares during the last quarter. Finally, EP Wealth Advisors LLC acquired a new stake in shares of Omnicell in the first quarter worth $245,000. Institutional investors own 97.70% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on OMCL. Wells Fargo & Company upped their target price on shares of Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a research note on Monday, July 21st. Wall Street Zen cut Omnicell from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 9th. Bank of America lifted their price objective on Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a report on Friday, May 23rd. Finally, Piper Sandler cut their target price on Omnicell from $57.00 to $55.00 and set an "overweight" rating for the company in a research note on Monday, August 11th. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $46.71.

Omnicell Trading Up 4.5%

OMCL stock opened at $33.28 on Friday. The business has a fifty day moving average price of $30.67 and a 200 day moving average price of $31.17. Omnicell, Inc. has a fifty-two week low of $22.66 and a fifty-two week high of $55.74. The stock has a market capitalization of $1.53 billion, a price-to-earnings ratio of 66.56, a P/E/G ratio of 6.96 and a beta of 0.82. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.42 and a quick ratio of 1.24.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.45 EPS for the quarter, topping analysts' consensus estimates of $0.30 by $0.15. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The firm had revenue of $290.56 million for the quarter, compared to analyst estimates of $275.57 million. During the same quarter in the prior year, the firm earned $0.51 EPS. The company's revenue was up 5.0% on a year-over-year basis. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. Analysts expect that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.